Compare Nu Holdings Ltd (NU) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nu Holdings Ltd vs Sanofi SA — how do they compare? Nu Holdings Ltd trades at $15.06 (market cap $72.46B), while Sanofi SA trades at $43.12 (market cap $103.41B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays a 5.65% dividend while Nu Holdings Ltd pays none. Which is the better fit depends on your goals.
| NU | SNY | |
|---|---|---|
Market Cap | $72.46B | $103.41B |
Sector | Financials | Health |
52-Week High | $18.76 | $52.34 |
52-Week Low | $11.60 | $41.33 |
Enterprise Value | — | $123.44B |
Dividend Yield | — | 5.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NU Holdings stock trades at $15.33, down 0.26% today, with a bullish technical outlook and strong fundamental growth. The company reported record Q2 2026 results with $1 billion net income and 39% revenue growth year-over-year, driven by expanding customer base and AI integration. Analyst consensus is a Buy with a $17.20 price target, reflecting confidence in sustained profitability and market expansion in Brazil and Mexico.
The stock presents a compelling growth opportunity with robust earnings momentum and positive sentiment, though risks include credit quality concerns and competitive pressures. Upside potential exists if execution continues, but investors should monitor loan performance and macroeconomic factors in key markets.
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
